Loading clinical trials...

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension) | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

A 2-year Extension Study to Evaluate Long-term Effectiveness of Mavenclad® in Participants Who Have Completed Trial MS700568_0022 (MAGNIFY MS) (Magnify MS Extension)

NCT04783935•Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

View on ClinicalTrials.gov

Summary

The primary purpose of this study was to evaluate the long-term effectiveness of Mavenclad® tablets, in terms of disease activity and safety, in participants with highly-active relapsing multiple sclerosis (RMS) previously participating in the MAGNIFY MS trial MS700568\_0022 (NCT03364036).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participants of the MAGNIFY Multiple Sclerosis (MS) trial who received at least a single dose of cladribine tablets during the MAGNIFY MS trial and data on Magnetic resonance imaging (MRI) is available/acquired from at least parent study Month 18 or Month 24 visit and Expanded Disability Status Scale (EDSS) and relapse from parent study Month 24 visit
•Capable of giving signed informed consent

Exclusion Criteria

•Participant is considered by the Investigator, for any reason, to be an unsuitable candidate for the study
•Participation in other studies/trials

Locations (46)

Liverpool Hospital

Liverpool, Australia

John Hunter Hospital

New Lambton, Australia

Klinikum Klagenfurt

Klagenfurt, Austria

Paracelsus Medical University Salzburg

Salzburg, Austria

University of Alberta

Edmonton, Canada

Children's Hospital, London Health Sciences Centre- Pediatrics

London, Canada

Montreal Neurological Hospital

Montreal, Canada

MS Clinical Trials Group

Vancouver, Canada

Fakultni nemocnice Brno

Brno, Czechia

Fakultni nemocnice u sv. Anny v Brne

Brno, Czechia

Key Dates

Start Date

March 10, 2021

Primary Completion Date

September 21, 2023

Completion Date

September 21, 2023

Last Updated

January 22, 2025

Enrollment

219

ACTUAL participants

Conditions

Multiple Sclerosis

Interventions

Mavenclad®

DRUG

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

View study

RECRUITINGNA

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634

Multiple SclerosisMultiple Sclerosis-Relapsing-Remitting+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Intermittent Hypoxia in Persons With Multiple Sclerosis

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis